

# Paul Baas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/966102/publications.pdf>

Version: 2024-02-01

25  
papers

7,239  
citations

758635

12  
h-index

713013

21  
g-index

25  
all docs

25  
docs citations

25  
times ranked

10187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1540-1550.	6.3	5,456
2	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1276.	3.4	670
3	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.	157.7	306
4	Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1569-1576.	0.5	206
5	Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2019, 7, 260-270.	5.2	190
6	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	0.9	189
7	Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. <i>EBioMedicine</i> , 2020, 62, 103040.	2.7	35
8	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. <i>Translational Lung Cancer Research</i> , 2020, 9, 1169-1179.	1.3	30
9	Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 585-592.	5.2	30
10	Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a chemosensitive relapse: A single-arm phase II study (EORTC-08061). <i>European Journal of Cancer</i> , 2016, 54, 35-39.	1.3	17
11	Confocal Laser Endomicroscopy as a Guidance Tool for Pleural Biopsies in Malignant Pleural Mesothelioma. <i>Chest</i> , 2019, 156, 754-763.	0.4	17
12	BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 379-388.	1.9	13
13	Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response. <i>EBioMedicine</i> , 2021, 64, 103160.	2.7	13
14	Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical Responses. <i>Clinical Cancer Research</i> , 2018, 24, 1761-1770.	3.2	12
15	Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Cancer Lung Cancer Group studies and an independent study validation. <i>European Journal of Cancer</i> , 2014, 50, 2771-2782.	1.3	11
16	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, , .	0.5	11
17	Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. <i>Thorax</i> , 2022, 77, 1260-1267.	2.7	11
18	Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care. <i>Translational Lung Cancer Research</i> , 2020, 9, 1736-1748.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Treat it or Leave it: Immuno-Oncology in Mesothelioma Observed by the Eyes of Argus. Journal of Thoracic Oncology, 2018, 13, 1619-1622.	0.5	6
20	Trophoblast Glycoprotein is Associated With a Favorable Outcome for Mesothelioma and a Target for Antibody Drug Conjugates. Journal of Thoracic Oncology, 2018, 13, 1577-1587.	0.5	5
21	Nose in malignant mesotheliomaâ€”Prediction of response to immune checkpoint inhibitor treatment. European Journal of Cancer, 2021, 152, 60-67.	1.3	2
22	Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study. Lung Cancer, 2019, 138, 139-140.	0.9	0
23	Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. Journal of Geriatric Oncology, 2020, 11, 529-532.	0.5	0
24	Going Beyond Results of the PEMBRO-RT Trialâ€”Reply. JAMA Oncology, 2020, 6, 162.	3.4	0
25	Prognostic value of CYFRA 21.1 in malignant mesothelioma: A brief report of the randomized phase II trial NVALT19. Lung Cancer, 2021, 161, 197-199.	0.9	0